Cyclodextrins as pharmaceutical solubilizers

Villiers, 1891, Sur la fermentation de la fécule par l'action du ferment butyrique, Compt. Rend. Acad. Sci., 112, 536

Loftsson, 2007, Cyclodextrins and their pharmaceutical applications, Int. J. Pharm., 329, 1, 10.1016/j.ijpharm.2006.10.044

Schardinger, 1903, Über Thermophile Bakterien aus verschiedenen Speisen und Milch, sowie über einige Umsetzungsprodukte derselben in kohlenhydrathaltigen Nährlösungen, darunter krystallisierte Polysaccharide (Dextrine) aus Stärke, Z. Unters. Nahr.- Genussm., 6, 865, 10.1007/BF02067497

Schardinger, 1911, Bildung kristallisierter Polysaccharide (Dextrine) aus Stärkekleister durch Microben, Zentralbl. Bakteriol. Parasitenkd. Abt. II, 29, 188

Freudenberg, 1935, Über Schardinger Dextrine aus Stärke Liebigs, Ann. Chem., 518, 102, 10.1002/jlac.19355180107

Larsen, 2002, Large cyclodextrins, J. Incl. Phenom. Macrocycl. Chem., 43, 1, 10.1023/A:1020494503684

Ueda, 2006, Large-ring cyclodextrins, 370

Cramer, 1954

1999, vol. 36

Oguma, 2003, Production of cyclodextrin and its applications, Trends Glycosci. Glycotechnol., 15, 91, 10.4052/tigg.15.91

Uekama, 2006, Recent aspects of cyclodextrin-based drug delivery systems, J. Incl. Phenom. Macrocycl. Chem., 56, 3, 10.1007/s10847-006-9052-y

Strickley, 2004, Solubilizing excipients in oral and injectable formulations, Pharm. Res., 21, 201, 10.1023/B:PHAM.0000016235.32639.23

Loftsson, 2004, Role of cyclodextrins in improving oral drug delivery, Am. J. Drug Deliv., 2, 261, 10.2165/00137696-200402040-00006

Davis, 2004, Cyclodextrin-based pharmaceutics: past, present and future, Nat. Rev., Drug Discov., 3, 1023, 10.1038/nrd1576

Avdeef, 2007, Solubility-excipient classification gradient maps, Pharm. Res., 24, 530, 10.1007/s11095-006-9169-0

Kim, 2004, Solubility enhancers for oral drug delivery, Am. J. Drug Deliv., 2, 113, 10.2165/00137696-200402020-00004

Loftsson, 2005, Cyclodextrins in drug delivery, Expert Opin. Drug Deliv., 2, 335, 10.1517/17425247.2.1.335

Szejtli, 2005, Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins, Eur. J. Pharm. Biopharm., 61, 115, 10.1016/j.ejpb.2005.05.006

Lantz, 2006, Estimation of association constants between oral malodor components and various native and derivatized cyclodextrins, Anal. Chim. Acta, 557, 184, 10.1016/j.aca.2005.10.005

Loftsson, 1996, Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization, J. Pharm. Sci., 85, 1017, 10.1021/js950534b

Uekama, 1998, Cyclodextrin drug carrier systems, Chem. Rev., 98, 2045, 10.1021/cr970025p

Szejtli, 1982

Szejtli, 1988

Stella, 1997, Cyclodextrins: their future in drug formulation and delivery, Pharm. Res., 14, 556, 10.1023/A:1012136608249

Frömming, 1994

Winkler, 2000, Hydration of β-cyclodextrin: a molecular dynamics simulation study, J. Comput. Aided Mol. Des., 14, 659, 10.1023/A:1008155230143

Bone, 2006, Dielectric studies of water clusters in cyclodextrins: relevance to the transition between slow and fast forms, J. Phys. Chem., B, 110, 20609, 10.1021/jp063811j

Hakkarainen, 2005, 1H NMR studies on the hydrogen-bonding network in mono-altro-β-cyclodextrin and its complex with adamantane-1-carboxylic acid, Carbohydr. Res., 340, 1539, 10.1016/j.carres.2005.03.016

Lichtenthaler, 1996, On the hydrophobic characteristics of cyclodextrins: computer-aided visualization of molecular lipophilicity patterns, Liebigs Ann. Chem., 27, 10.1002/jlac.199619960105

Bender, 1978

Schmid, 1989, Cyclodextrin glycosyltransferase production; yield enhancement by overexpression of cloned genes, Tibtech, 7, 244, 10.1016/0167-7799(89)90015-2

Schmid, 1991, Preparation and application of γ-cyclodextrin, 25

Sicard, 1987, Biosynthesis of cycloglycosyltransferase and obtention of enzymatic reaction products, 77

Rajewski, 1996, Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery, J. Pharm. Sci., 85, 1142, 10.1021/js960075u

Irie, 1997, Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation, J. Pharm. Sci., 86, 147, 10.1021/js960213f

Thompson, 1997, Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals, Crit. Rev. Ther. Drug Carr. Syst., 14, 1, 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10

2002, vol. 909, 41

Lina, 2004, Subchronic oral toxicity studies with α-cyclodextrin in rats, Regul. Toxicol. Pharmacol., 39, S14, 10.1016/j.yrtph.2004.05.006

Lina, 2004, Subchronic (13-week) oral toxicity study of α-cyclodextrin in dogs, Regul. Toxicol. Pharmacol., 39, S27, 10.1016/j.yrtph.2004.05.005

Bellringer, 1995, β-Cyclodextrin: 52-week toxicity studies in the rat and dog, Food Chem. Toxicol., 367, 10.1016/0278-6915(94)00149-I

Munro, 2004, Safety assessment of γ-cyclodextrin, Regul. Toxicol. Pharmacol., 39, S3, 10.1016/j.yrtph.2004.05.008

Koutsou, 1999, Gastrointestinal tolerance of γ-cyclodextrin in humans, Food Addit. Contam., 16, 313, 10.1080/026520399283984

Gould, 2005, 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review, Food Chem. Toxicol., 43, 1451, 10.1016/j.fct.2005.03.007

M.E. Brewster, C. Mackie, A. Lampo, M. Noppe, T. Loftsson, The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines, in: P. Augustijns and M.E. Brewster (Eds.), Solvent systems and their selection in pharmaceutics and biopharmaceutics, American Association of Pharmaceutical Scientists and Springer: New York, (2007), pp. 221-256.

2003, Physician’s Desk Reference

1997, Toxicological data

Uekama, 2004, Design and evaluation of cyclodextrin-based drug formulation, Chem. Pharm. Bull., 52, 900, 10.1248/cpb.52.900

Antlsperger, 1996, Toxicological comparison of cyclodextrins, 149

Hirayama, 1999, Cyclodextrin-based controlled release systems, Adv. Drug Deliv. Rev., 36, 125, 10.1016/S0169-409X(98)00058-1

Challa, 2005, Cyclodextrin in drug delivery: an updated review, AAPS PharmSciTech, 6, E329, 10.1208/pt060243

Vromans, 1989, Mechanism of dissolution of drug-cyclodextrin complexes. A pragmatic approach, Acta Pharm. Technol., 35, 250

Amidon, 1995, Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023/A:1016212804288

Dressman, 1998, Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm. Res., 15, 11, 10.1023/A:1011984216775

Yu, 2002, Biopharmaceutics classification system: the scientific basis for biowaiver extensions, Pharm. Res., 19, 921, 10.1023/A:1016473601633

Loftsson, 2002, Cyclodextrins and the biopharmaceutical classification system of drugs, J. Incl. Phenom. Macrocycl. Chem., 44, 63, 10.1023/A:1023088423667

Pitha, 1992, Preparation of drug-hydroxypropyl cyclodextrin complexes by a method using ethanol or aqueous ammonium hydroxide as cosolubilizers, Int. J. Pharm., 80, 253, 10.1016/0378-5173(92)90282-7

Pitha, 1992, Effect of ethanol on formation of inclusion complexes of hydroxypropyl cyclodextrin with testosterone or with methyl orange, Int. J. Pharm., 80, 243, 10.1016/0378-5173(92)90281-6

Stella, 1999, Mechanisms of drug release from cyclodextrin complexes, Adv. Drug Deliv. Rev., 36, 3, 10.1016/S0169-409X(98)00052-0

Connors, 1995, Population characteristics of cyclodextrin complex stabilities in aqueous solution, J. Pharm. Sci., 84, 843, 10.1002/jps.2600840712

Connors, 1997, The stability of cyclodextrin complexes in solution, Chem. Rev., 97, 1325, 10.1021/cr960371r

Rao, 2003, When can cyclodextrins be considered for solubilizing purposes?, J. Pharm. Sci., 92, 927, 10.1002/jps.10341

Aoyama, 1992, Host-guest complexation of oligosaccharides: interaction of maltodextrins with hydrophobic fluorescence probes in water, Tetrahedron Lett., 33, 3775, 10.1016/0040-4039(92)80022-C

1991, vol. 3

Loftsson, 1996, The effect of water-soluble polymers on aqueous solubility of drugs, Int. J. Pharm., 127, 293, 10.1016/0378-5173(95)04207-5

Tomasik, 1998, Complexes of starch with inorganic guests, 263, 10.1016/S0065-2318(08)60046-3

Tomasik, 1998, Complexes of starch with organic guests, 345, 10.1016/S0065-2318(08)60047-5

Gabelica, 2002, On the specificity of cyclodextrin complexes detected by electrospray mass spectrometry, J. Am. Soc. Mass Spectrom., 13, 946, 10.1016/S1044-0305(02)00416-6

Correia, 2002, Study of inclusion complexes of acridine with β- and (2,6-di-O-methyl)-β-cyclodextrin by use of solubility diagrams and NMR spectroscopy, J. Phys. Org. Chem., 15, 647, 10.1002/poc.528

Andronati, 1996, Inclusion compounds of psychotropic agents and cyclodextrins, J. Incl. Phenom. Macrocycl. Chem., 24, 175, 10.1007/BF01053430

Loftsson, 2002, Self-association and cyclodextrin solubilization of drugs, J. Pharm. Sci., 91, 2307, 10.1002/jps.10226

Loftsson, 2004, Self-association of cyclodextrins and cyclodextrin complexes, J. Pharm. Sci., 93, 1091, 10.1002/jps.20047

Chadha, 2004, Account of analytical techniques employed for the determination of thermodynamics of inclusion complexation of drugs with cyclodextrins, J. Sci. Ind. Res., 63, 211

Higuchi, 1965, vol. 4, 117

Connons, 1996, Measurement of cyclodextrin complex stability constants, vol. 3, 205

Brewster, 1999, Complexation — use of cyclodextrins to improve pharmaceutical properties of intramuscular formulations, 307

Loftsson, 2005, Evaluation of cyclodextrin solubilization of drugs, Int. J. Pharm., 302, 18, 10.1016/j.ijpharm.2005.05.042

Higuchi, 1970, Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies, J. Pharm. Sci., 59, 1601, 10.1002/jps.2600591112

Peeters, 2002, Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4 and 7, J. Pharm. Sci., 91, 1414, 10.1002/jps.10126

Pourmokhtar, 2005, Enhanced stability of sulfamethazole and trimethoprim against oxidation using hydroxypropyl-β-cyclodextrin, Pharmazie, 60, 837

Chen, 1996, Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in-vivo permeability of alkannin/shikonin enantiomers, Int. J. Pharm., 141, 171, 10.1016/0378-5173(96)04634-0

Bekers, 1990, Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins, J. Pharm. Biomed. Anal., 8, 671, 10.1016/0731-7085(90)80100-4

Brewster, 1991, Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride, Int. J. Pharm., 79, 289, 10.1016/0378-5173(92)90121-H

Cervero, 2000, Inclusion complexes of dimethyl 2,6-naphthalenedicarboxylate with α- and β-cyclodextrins in aqueous medium: thermodynamics and molecular mechanics study, J. Phys. Chem., B, 104, 1572, 10.1021/jp993418w

Mohanty, 2006, Host-guest complexation of neutral red with macrocyclic host molecules: contrasting pKa shifts and binding affinities for cucurbit[7]uril and β-cyclodextrin, J. Phys. Chem., B, 110, 5132, 10.1021/jp056411p

Yang, 2000, The performance of the Benesi-Hildebrand method in measuring the binding constants of the cyclodextrin complexation, Anal. Sci., 16, 537, 10.2116/analsci.16.537

Crane, 2002, Cyclodextrin inclusion complexes with a solvatochrome fluorescent probe, J. Chem. Educ., 79, 1261, 10.1021/ed079p1261

Abdel-Shafi, 2007, Spectroscopic studies on the inclusion complex of 2-naphtol-6-sulfonate with β-cyclodextrin, Spectrochim. Acta, Part A: Mol. Biomol. Spectrosc., 66A, 732, 10.1016/j.saa.2006.04.018

Schneider, 1993, Supermolecular Chemistry. 36. NMR spectroscopy and molecular-mechanics calculations in supermolecular chemistry, Rec. Trav. Chem., 112, 412, 10.1002/recl.19931120618

Ganza-Gonzalez, 1994, A proton nuclear magnetic resonance study of the inclusion of naproxen with β-cyclodextrin, Int. J. Pharm., 106, 179, 10.1016/0378-5173(94)90001-9

Piel, 2001, A nuclear magnetic resonance study of the miconazole-β-cyclodextrin inclusion complex in an acidic medium: determination of the structure and stability constant, STP Pharm. Sci., 11, 235

Masson, 2003, Estimation of 19F-NMR as a tool for investigation of drug-cyclodextrin complexes, Drug Dev. Ind. Pharm., 29, 107, 10.1081/DDC-120016689

Polyakov, 2004, Inclusion complexes of carotenoids with cyclodextrins: 1H-NMR, EPR and optical studies, Free Radic. Biol. Med., 36, 872, 10.1016/j.freeradbiomed.2003.12.009

Hofler, 1996, Determination of binding energies between cyclodextrins and aromatic guest molecules by calorimetry, J. Incl. Phenom. Macrocycl. Chem., 25, 81, 10.1007/BF01041541

Wenz, 1998, Inclusion of pharmaceutical drugs in cyclodextrins as measured by titration microcalorimetry, Polym. Prepr., 39, 202

Li, 1983, Complex formation between α-cyclodextrin and 4-substituted phenols studies by potentiometric and competitive spectrophotometric methods, J. Pharm. Sci., 72, 1333, 10.1002/jps.2600721124

Davies, 1998, Stability constants of α-cyclodextrin complexes of para-substituted aromatic ketones in aqueous solution, J. Chem. Soc., Perkin Trans., 2, 193, 10.1039/a701470h

Masson, 2005, Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical consideration, Chem. Pharm. Bull., 53, 958, 10.1248/cpb.53.958

Moeder, 1996, Determination of stoichiometric coefficients and apparent stability constants for α- and β-CD complexes of terpenes using reversed-phase liquid chromatography, J. Chromatogr., A, 736, 1, 10.1016/0021-9673(95)01276-1

Loukas, 1994, γ-Cyclodextrin complex of a new organophosphate insecticide. Determination of stability constant with HPLC, J. Agric. Food Chem., 42, 944, 10.1021/jf00040a020

Durham, 1994, Molecular modeling of the inclusion complexes between β-cyclodextrin and (R)/(S)-methylphenobarbitone and its application to HPLC, Chirality, 6, 240, 10.1002/chir.530060405

Fukahori, 2004, Ultrasonic relaxation due to inclusion complex of amino acid by β-cyclodextrin in aqueous solution, J. Acoust. Soc. Am., 115, 2325, 10.1121/1.1695432

Cirri, 2005, Determination of stability constant values of flurbiprofen-cyclodextrin complexes using different techniques, J. Pharm. Biomed. Anal., 37, 995, 10.1016/j.jpba.2004.09.044

Landy, 2007, Development of a competitive continuous variation plot for the determination of inclusion compound stoichiometry, J. Incl. Phenom. Macrocycl. Chem., 57, 409, 10.1007/s10847-006-9226-7

Loukas, 1997, Measurement of molecular association in drug: cyclodextrin inclusion complexes with improved 1H NMR studies, J. Pharm. Pharmacol., 49, 944, 10.1111/j.2042-7158.1997.tb06021.x

2006

Ross, 1996, Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes, Biophys. J., 71, 2144, 10.1016/S0006-3495(96)79415-8

Tong, 1991, Microcalorimetric investigation of the complexation between 2-hydroxypropyl-β-cyclodextrin and amine drugs with diphenylmethyl functionality, J. Pharm. Biomed. Anal., 9, 1139, 10.1016/0731-7085(91)80056-F

Gelb, 1982, Cycloamylose complexation of organic anions, J. Phys. Chem., 87, 3349, 10.1021/j100240a033

Gelb, 1981, Binding mechanisms in cyclohexaamylose complexes, J. Am. Chem. Soc., 103, 1750, 10.1021/ja00397a027

Kurihara, 1990, Improvement of some pharmaceutical properties of cloprost by β- and γ-cyclodextrin complexation, J. Incl. Phenom. Mol. Recognit. Chem., 8, 363, 10.1007/BF01041192

Matsuyama, 1987, Thermodynamics of binding of aromatic amino acids to α-, β- and γ-cyclodextrin, Drug Dev. Ind. Pharm., 13, 2687, 10.3109/03639048709022084

Alvira, 2000, Factors influencing β-cyclodextrin inclusion complex formation, Recent Res. Dev. Chem. Phys., 1, 89

Marques, 1994, Application of cyclodextrins. Thermodynamic aspects of cyclodextrin complexes, Rev. Port. Farm., 44, 85

Liu, 1999, Novel prediction for the driving force and guest orientation in the complexation of α- and β-cyclodextrin with benzene derivatives, J. Phys. Chem., B, 103, 3461, 10.1021/jp984545f

Pinjari, 2006, Molecular electrostatic potentials and hydrogen bonding in α-, β-, and γ-cyclodextrins, J. Phys. Chem., A, 110, 13073, 10.1021/jp065169z

Bergeron, 1984, Cycloamylose-substrate binding, 391

Liu, 2002, The driving forces in the inclusion complexation of cyclodextrins, J. Incl. Phenom. Macrocycl. Chem., 42, 1, 10.1023/A:1014520830813

Liu, 1999, Regression analysis for the host-guest interaction of β-cyclodextrin with mono- and 1, 4-disubstituted benzenes, J. Incl. Phenom. Macrocycl. Chem., 34, 413, 10.1023/A:1008069209462

Magnusdottir, 2002, Self-association and cyclodextrin solubilization of NSAID's, J. Incl. Phenom. Macrocycl. Chem., 44, 213, 10.1023/A:1023079322024

Loftsson, 2003, The effect of organic salts on the cyclodextrin solubilization of drugs, Int. J. Pharm., 262, 101, 10.1016/S0378-5173(03)00334-X

Loftsson, 1999, Methods to enhance the complexation efficiency of cyclodextrins, STP Pharm. Sci., 9, 237

Loftsson, 2004, The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs, J. Drug Del. Sci. Tech., 14, 35, 10.1016/S1773-2247(04)50003-5

Jug, 2004, Hydroxy methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-β-cyclodextrin inclusion complex, Pharmazie, 59, 686

Ribeiro, 2003, Physicochemical investigations on the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state, Eur. J. Pharm. Sci., 20, 253, 10.1016/S0928-0987(03)00199-4

Cirri, 2006, Simultaneous effect of cyclodextrin complexation, pH and hydrophilic polymers on naproxen solubilization, J. Pharm. Biomed. Anal., 42, 126, 10.1016/j.jpba.2005.11.029

Valero, 2003, Ternary naproxen:β-cyclodextrin:polyethylene glycol complex formation, Int. J. Pharm., 265, 141, 10.1016/j.ijpharm.2003.07.003

Jug, 2004, Multicomponent complexes of piroxicam with cyclodextrin and hydroxypropyl methylcellulose, Drug Dev. Ind. Pharm., 30, 1051, 10.1081/DDC-200040245

Ribeiro, 2003, Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes, Chem. Pharm. Bull., 51, 914, 10.1248/cpb.51.914

Krishnamoorthy, 1996, Complexation of weak acids and basis with cyclodextrins: Effects of substrate ionization on the estimation and interpretation of association constants, Int. J. Pharm. Adv., 1, 330

Redenti, 2001, Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications, J. Pharm. Sci., 90, 979, 10.1002/jps.1050

Redenti, 2000, Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications, J. Pharm. Sci., 89, 1, 10.1002/(SICI)1520-6017(200001)89:1<1::AID-JPS1>3.0.CO;2-W

Ribeiro, 2005, Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies, Eur. J. Pharm. Sci., 24, 1, 10.1016/j.ejps.2004.09.003

Loftsson, 2004, Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs, Pharmazie, 59, 25

Mura, 2003, Ternary systems of naproxen with hydroxypropyl-β-cyclodextrin and amino acids, Int. J. Pharm., 260, 293, 10.1016/S0378-5173(03)00265-5

Li, 1998, Combined effect of complexation and pH on solubilization, J. Pharm. Sci., 87, 1535, 10.1021/js9801889

Loftsson, 2007, The complexation efficiency, J. Incl. Phenom. Macrocycl. Chem., 57, 545, 10.1007/s10847-006-9247-2

Usui, 1997, Inhibitory effects of water-soluble polymers on precipitation of RS-8359, Int. J. Pharm., 154, 59, 10.1016/S0378-5173(97)00129-4

Attwood, 1983, Surfactant systems, 361

Myers, 1988, 142

Malmsten, 2002

Loftsson, 1998, The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin, Int. J. Pharm., 163, 115, 10.1016/S0378-5173(97)00371-2

Valero, 2004, Naproxen:hydroxypropyl-β-cyclodextrin:polyvinylpyrrolidone ternary complex formation, J. Incl. Phenom. Macrocycl. Chem., 48, 157, 10.1023/B:JIPH.0000022522.84387.db

Yamakawa, 2003, Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin, J. Control. Release, 86, 101, 10.1016/S0168-3659(02)00367-X

Harada, 1997, Design and construction of supramolecular architectures consisting of cyclodextrins and polymers, Adv. Polym. Sci., 133, 141, 10.1007/3-540-68442-5_4

Torres-Labandeira, 1990, Oversaturated solutions of drug in hydroxypropylcyclodextrins: parenteral preparation of pancratistatin, J. Pharm. Sci., 80, 384, 10.1002/jps.2600800421

Brewster, 2007, Solubilization of itraconazole as a function of cyclodextrin structural space, J. Incl. Phenom. Macrocycl. Chem., 57, 561, 10.1007/s10847-006-9249-0

Xiang, 2002, Stable supersaturated aqueous solution of Silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified β-cyclodextrin, Pharm. Res., 19, 1215, 10.1023/A:1019862629357

Wang, 1993, Release characteristics of nifedipine from 2-hydroxypropyl-β-cyclodextrin complex during storage and its modification of hybridizing polyvinylpyrrolidone K-30, Chem. Pharm. Bull., 41, 1822, 10.1248/cpb.41.1822

Uekama, 1992, Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal-growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30, J. Pharm. Pharmacol., 44, 73, 10.1111/j.2042-7158.1992.tb03564.x

Jaconson, 1999, Cyclodextrin inclusion complexes of antimycotics intended to act in the oral cavity — drug supersaturation, toxicity to TR166 cells and release from a delivery system, Eur. J. Pharm. Biopharm., 48, 217, 10.1016/S0939-6411(99)00043-0

Castillo, 1999, Preparation and characterization of albendazole β-cyclodextrin complexes, Drug Dev. Ind. Pharm., 25, 1241, 10.1081/DDC-100102294

Pedersen, 1998, A genuine clotrimazole γ-cyclodextrin inclusion complex-isolation, antimycotic activity, toxicity and unusual dissolution rate, Int. J. Pharm., 176, 121, 10.1016/S0378-5173(98)00310-X

Pedersen, 1998, An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation and biological efficacy example, Int. J. Pharm., 165, 57, 10.1016/S0378-5173(97)00431-6

Pedersen, 1999, Cyclodextrin inclusion complexes of miconazole and econazole – isolation, toxicity on human cells and confirmation of a new interpretation of the drug supersaturation phenomenon, Drug Dev. Ind. Pharm., 25, 463, 10.1081/DDC-100102196

Leichtman, 2007, Impact of antinucleants on transdermal delivery of testosterone from a spray, J. Pharm. Sci., 96, 84, 10.1002/jps.20670

Dias, 2003, The effect of β-cyclodextrin on the permeation of diclofenac from supersaturated solutions, Int. J. Pharm., 263, 173, 10.1016/S0378-5173(03)00366-1

Iervolino, 2001, Penetration enhancement of ibuprofen from supersaturated solutions through human skin, Int. J. Pharm., 212, 131, 10.1016/S0378-5173(00)00603-7

Iervolino, 2000, Membrane penetration enhancement of ibuprofen using supersaturation, Int. J. Pharm., 198, 229, 10.1016/S0378-5173(00)00346-X

Macie, 1986, Crystal growth in pharmaceutical formulation, Pharm. Intl., 233

Raghvan, 2001, Crystallization of hydrocortisone acetate: influence of polymers, Int. J. Pharm., 212, 213, 10.1016/S0378-5173(00)00610-4

Raghavan, 2003, Formation and stabilization of triclosan colloidal suspension using supersaturated systems, Int. J. Pharm., 261, 153, 10.1016/S0378-5173(03)00299-0

Gao, 2004, Enhanced oral bioavailability of a poorly water-soluble drug PNU-91325 by supersaturable formulations, Drug Dev. Ind. Pharm., 30, 221, 10.1081/DDC-120028718

Terayama, 2004, Preparation of stable aqueous suspension of a hydrophobic drug with polymers, Colloids Surf., B Biointerfaces, 39, 159, 10.1016/j.colsurfb.2004.09.005

Simonelli, 1970, Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone, J. Pharm. Sci., 59, 633, 10.1002/jps.2600590512

Rodriguez-Hornedo, 1999, Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems, J. Pharm. Sci., 88, 651, 10.1021/js980490h

Yokoi, 2005, Effect of sugar esters and hydroxypropyl methylcellulose on the physicochemical stability of amorphous pivoxil in aqueous suspension, Int. J. Pharm., 290, 91, 10.1016/j.ijpharm.2004.11.020

Pedersen, 1997, The bioavailability difference between genuine cyclodextrin inclusion complexes and freeze-dried or ground drug cyclodextrin samples may be due to supersaturation differences, Drug Dev. Ind. Pharm., 23, 331, 10.3109/03639049709149812

Lipinski, 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev., 23, 3, 10.1016/S0169-409X(96)00423-1

Lipinski, 2001, Avoiding investment in doomed drugs, Curr. Drug Discov., 1, 17

Prentis, 1988, Pharmaceutical innovation by seven UK-owned pharmaceutical companies, Br. J. Clin. Pharmacol., 2, 387, 10.1111/j.1365-2125.1988.tb03318.x

Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat. Rev., Drug Discov., 2, 711, 10.1038/nrd1470

Liu, 2000

Abdoh, 2007, Changes in the conformational structure, microscopic and macroscopic pKa's of meloxicam on complexation with natural and modified cyclodextrins, Pharmazie, 62, 55

Beni, 2007, Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities, Eur. J. Pharm. Sci., 30, 167, 10.1016/j.ejps.2006.10.008

Morales, 2007, Study of the interaction between S(−)bupivacaine and 2-hydroxypropyl-β-cyclodextrin, Int. J. Pharm., 331, 99, 10.1016/j.ijpharm.2006.09.054

Figeiras, 2007, Interaction of omeprazole with a methylated derivative of β-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulations, Pharm. Res., 24, 377, 10.1007/s11095-006-9161-8

Al Omari, 2006, Sidenafil/cyclodextrin complexation: stability constants, thermodynamics and guest-host interactions probed by 1H NMR and molecular modeling studies, J. Pharm. Biomed. Anal., 41, 857, 10.1016/j.jpba.2006.01.055

Lahiani-Skiba, 2006, Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems, Drug Dev. Ind. Pharm., 32, 1043, 10.1080/03639040600897093

Lee, 2007, Physicochemical characterization and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexes with β-cyclodextrin, Int. J. Pharm., 316, 29, 10.1016/j.ijpharm.2006.02.035

Uzqueda, 2006, Characterization of complexes between naftifine and cyclodextrins in solution and in the solid state, Pharm. Res., 23, 980, 10.1007/s11095-006-9903-7

Ventura, 2006, Physico-chemical characterization of disoxaril-dimethyl-β-cyclodextrin inclusion complex and in vitro permeation studies, Eur. J. Med. Chem., 41, 233, 10.1016/j.ejmech.2005.11.002

Perry, 2006, The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins, J. Pharm. Sci., 95, 146, 10.1002/jps.20525

Cappello, 2006, Improvement of solubility and stability of valsartan by hydroxypropyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 54, 289, 10.1007/s10847-005-9004-y

Torne, 2006, Inclusion complexation of anti-HIV drug with β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 56, 253, 10.1007/s10847-006-9092-3

Shen, 2006, Determination of the inclusion complex between gossypol and β-cyclodextrin, Spectrochim. Acta, Part A, 65A, 169, 10.1016/j.saa.2005.09.045

Al Omari, 2006, Effect of buffer species on the inclusion complexation of acidic drug celecoxib with cyclodextrin in solution, J. Incl. Phenom. Macrocycl. Chem., 55, 247, 10.1007/s10847-005-9041-6

Jadhav, 2006, Interaction of valdecoxib with β-cyclodextrin: experimental and molecular modeling studies, J. Incl. Phenom. Macrocycl. Chem., 56, 261, 10.1007/s10847-006-9093-2

Pinto, 2005, Physico-chemical characterization of benzocaine-β-cyclodextrin inclusion complexes, J. Pharm. Biomed. Anal., 39, 956, 10.1016/j.jpba.2005.06.010

Tommasini, 2005, The inclusion complexes of hesperetin and its 7-rhamnoglucoside with (2-hydroxypropyl)-β-cyclodextrin, J. Pharm. Biomed. Anal., 39, 572, 10.1016/j.jpba.2005.05.009

Zheng, 2005, Physicochemical and structural characterization of quercetin-β-cyclodextrin complexes, J. Pharm. Sci., 94, 1079, 10.1002/jps.20325

Yap, 2005, Characterization of the 1,3-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis, Eur. J. Pharm. Sci., 25, 49, 10.1016/j.ejps.2005.01.021

Rajendrakumar, 2005, Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in the rat, Eur. J. Pharm. Biopharm., 60, 39, 10.1016/j.ejpb.2004.12.005

Larsen, 2005, Phase solubility and structure of the inclusion complexes of prednisolone and 6α-methyl prednisolone with various cyclodextrins, J. Pharm. Sci., 94, 507, 10.1002/jps.20192

Loftsson, 2005, Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: effect of ionization and polymers, J. Incl. Phenom. Macrocycl. Chem., 53, 109, 10.1007/s10847-004-6048-3

El-Barghouthi, 2005, Host-guest interactions of risperidone with natural and modified cyclodextrins: phase–solubility, thermodynamics and molecular modeling studies, J. Incl. Phenom. Macrocycl. Chem., 53, 15, 10.1007/s10847-004-8212-1

Sinha, 2005, Complexation of celecoxib with β-cyclodextrin: characterization of the interaction in solution and in solid state, J. Pharm. Sci., 94, 676, 10.1002/jps.20287

Calabro, 2004, Effects of α- and β-cyclodextrin complexation on the physico-chemical properties and antioxidant activity of some 3-hydroxyflavones, J. Pharm. Biomed. Anal., 35, 365, 10.1016/j.jpba.2003.12.005

Mukne, 2004, Triamterene-β-cyclodextrin systems: preparation, characterization and in vivo evaluation, AAPS PharmSciTech, 5, 1, 10.1007/BF02830587

Sætern, 2004, Effect of hydroxypropyl-β-cyclodextrin-complexation and pH on the solubility of camptothecin, Int. J. Pharm., 284, 61, 10.1016/j.ijpharm.2004.07.014

Yanez, 2004, Spectrophotometric and electrochemical study of the inclusion complex between β-cyclodextrin and furnidipine, J. Pharm. Biomed. Anal., 35, 51, 10.1016/j.jpba.2003.12.015

Rawat, 2004, Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes, Eur. J. Pharm. Biopharm., 57, 263, 10.1016/j.ejpb.2003.10.020

Castro-Hermida, 2004, Anticryptosporidial activity of furan derivative G1 and its inclusion complex with β-cyclodextrin, J. Pharm. Sci., 93, 197, 10.1002/jps.10528

Yamamura, 2004, Factors controlling the complex architecture of native and modified cyclodextrins with dipeptide (Z–Glu–Tyr) studies by microcalorimetry and NMR spectroscopy: critical effects of peripheral bis-trimethylamination and cavity size, J. Am. Chem. Soc., 126, 14224, 10.1021/ja046612r

Aki, 2004, Multimodal inclusion complexes of ampicillin with β-cyclodextrin in aqueous solution, Thermochim. Acta, 416, 87, 10.1016/j.tca.2003.01.004

Rajendrakumar, 2004, Comparative study on co-ground products of rofecoxib with β-cyclodextrin and its sulfobutyl ether-7 derivative in solution and in the solid state, J. Incl. Phenom. Macrocycl. Chem., 49, 259, 10.1023/B:JIPH.0000048314.41966.65

Vlachou, 2003, Preparation and characterization of the inclusion complex of furosemide with hydroxypropyl-β-cyclodextrin, J. Biomater. Appl., 17, 197, 10.1177/0885328203017003557

Koontz, 2003, Formation of natamycin: cyclodextrin inclusion complexes and their characterization, J. Agric. Food Chem., 51, 7106, 10.1021/jf030332y

Waleczek, 2003, Phase solubility studies of pure (−)-α-bisbolol and chamomile essential oil with β-cyclodextrin, Eur. J. Pharm. Biopharm., 55, 247, 10.1016/S0939-6411(02)00166-2

Liu, 2003, Inclusion of acitretine into cyclodextrin: phase solubility, photostability and physicochemical characterization, J. Pharm. Sci., 92, 2449, 10.1002/jps.10495

Holvoet, 2003, Preparation and in-vivo release rate of fentanyl-cyclodextrin complexes for prolonged action in epidural analgesia, Int. J. Pharm., 265, 13, 10.1016/S0378-5173(03)00368-5

Rawat, 2003, Rofecoxib-β-cyclodextrin inclusion complex for solubility enhancement, Pharmazie, 58, 639

Illapakurthy, 2003, Interaction of artemisinin and its related compounds with hydroxypropyl-β-cyclodextrin in solution state: experimental and molecular-modeling studies, J. Pharm. Sci., 92, 649, 10.1002/jps.10319

Taneri, 2003, Influence of cyclodextrin complexation on the physicochemical and biopharmaceutical properties of ketoconazole, J. Incl. Phenom. Macrocycl. Chem., 47, 15, 10.1023/B:JIPH.0000003875.46691.f6

Chen, 2003, Inclusion complex of carprofen with hydroxypropyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 46, 111, 10.1023/A:1025699207208

Barbato, 2003, Diclofenac/β-cyclodextrin binary systems: a study in solution and in the solid state, J. Incl. Phenom. Macrocycl. Chem., 46, 179, 10.1023/A:1026303516401

Tavornvipas, 2002, Some pharmaceutical properties of a new branched cyclodextrin, 6-O-α-(4-O-α-d-glucuronyl)-d-glucosyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem., 44, 391, 10.1023/A:1023067232328

Tavornvipas, 2002, 6-O-α-(4-O-α-d-glucoronyl-d-glucosyl-β-cyclodextrin: solubilizing ability and some cellular effects, Int. J. Pharm., 249, 199, 10.1016/S0378-5173(02)00537-9

De Bie, 1998, Disposition of 14C-γ-cyclodextrin in germ-free and conventional rats, Regul. Toxicol. Pharmacol., 27, 150, 10.1006/rtph.1998.1219

Van Ommen, 2004, Disposition of 14C-α-cyclodextrin in germ-free and conventional rats, Regul. Toxicol. Pharmacol., 39, S57, 10.1016/j.yrtph.2004.05.011

Antlsperger, 1992, New aspects in cyclodextrin toxicology, 277

Matsuda, 1983, Acute toxicity study of γ-cyclodextrin (γ-CD) in mice and rats, Ogo Yakuri (Pharmacometrics),, 26, 287

2004, vol. 2